Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.
| 8.65 | |
| 8.91 | |
| - | |
| 9.046 | |
| 8.41 | |
| 2.35-11.55 | |
| 594 M | |
| 66 785 K | |
| 0 | |
| -0.0614 | |
| -0.328 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
SEATTLE and CAMBRIDGE, United Kingdom, July 20, 2023 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM) today announced that it has completed a review of its business, including the status ...
Presented initial preclinical data from ETX-123, Eliem's lead Kv7 program candidate, demonstrating a promising profile and confirming the proposed mechanism of action on neuronal excitability Additio...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
